» Articles » PMID: 25837032

Validation of Two Predictive Models for Survival in Pulmonary Arterial Hypertension

Abstract

The French Pulmonary Hypertension Network (FPHN) registry and the Registry to Evaluate Early And Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL) have developed predictive models for survival in pulmonary arterial hypertension (PAH). In this collaboration, we assess the external validity (or generalisability) of the FPHN ItinérAIR-HTAP predictive equation and the REVEAL risk score calculator. Validation cohorts approximated the eligibility criteria defined for each model. The REVEAL cohort comprised 292 treatment-naïve, adult patients diagnosed <1 year prior to enrolment with idiopathic, familial or anorexigen-induced PAH. The FPHN cohort comprised 1737 patients with group 1 PAH. Application of FPHN parameters to REVEAL and REVEAL risk scores to FPHN demonstrated estimated hazard ratios that were consistent between studies and had high probabilities of concordance (hazard ratios of 0.72, 95% CI 0.64-0.80, and 0.73, 95% CI 0.70-0.77, respectively). The REVEAL risk score calculator and FPHN ItinérAIR-HTAP predictive equation showed good discrimination and calibration for prediction of survival in the FPHN and REVEAL cohorts, respectively, suggesting prognostic generalisability in geographically different PAH populations. Once prospectively validated, these may become valuable tools in clinical practice.

Citing Articles

Management of pulmonary hypertension in special conditions.

Preston I, Howard L, Langleben D, Lichtblau M, Pulido T, Souza R Eur Respir J. 2024; 64(4).

PMID: 39209477 PMC: 11525332. DOI: 10.1183/13993003.01180-2024.


Risk stratification and treatment goals in pulmonary arterial hypertension.

Dardi F, Boucly A, Benza R, Frantz R, Mercurio V, Olschewski H Eur Respir J. 2024; 64(4).

PMID: 39209472 PMC: 11525341. DOI: 10.1183/13993003.01323-2024.


Cardiac Arrhythmias in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Mechanistic Insights, Pathophysiology, and Outcomes.

Abouzaid A, Ali K, Jatoi S, Ahmed M, Ahmad G, Nazim A Ann Noninvasive Electrocardiol. 2024; 29(5):e70010.

PMID: 39205610 PMC: 11358588. DOI: 10.1111/anec.70010.


Prognostic Value of Serial Risk Stratification in Adult and Pediatric Pulmonary Arterial Hypertension: A Systematic Review.

Lokhorst C, van der Werf S, Berger R, Douwes J J Am Heart Assoc. 2024; 13(13):e034151.

PMID: 38904230 PMC: 11255703. DOI: 10.1161/JAHA.123.034151.


A prognostic model for systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study.

Qu J, Li M, Zhang X, Zhang M, Zuo X, Zhu P Respir Res. 2023; 24(1):220.

PMID: 37689662 PMC: 10492375. DOI: 10.1186/s12931-023-02522-2.